- HMO breadth matters: Breast milk contains over 150 distinct HMO structures with overlapping protective functions — a single-HMO supplement captures only a fraction of that activity.
- kpHMO™, the proprietary human milk bioactive ingredient designed and owned exclusively by kēpos, mirrors the full oligosaccharide spectrum of breast milk, covering neutral, fucosylated, and sialylated HMO types.
- kēpos includes effera™, a recombinant human lactoferrin — the same protein found in breast milk — which a 2026 RCT found produced distinct gut microbiome effects compared to bovine lactoferrin (PMID 42178844).
- Research shows HMO combinations shift the gut microbiota more robustly than single compounds, with clinical benefits documented in both healthy adults and those with gut conditions like IBS.
- If you're evaluating HMO supplements, the science points clearly toward multi-HMO coverage + human lactoferrin as the most evidence-aligned approach for adult gut health.
The HMO supplement market is growing fast — and with growth comes more choices and more confusion. Two brands that come up frequently in gut health conversations are kēpos and LayerOrigin PureHMO. Both contain human milk oligosaccharides. But when you look closely at the science — and the ingredients — the differences are significant.
This isn't an attack on any competitor. It's a research-based breakdown of what the science says about HMO supplementation design: specifically, why the number of HMO types matters, and why the lactoferrin source makes a measurable difference in adult gut health outcomes. The goal is to help you understand what you're evaluating so you can make an informed decision.
What Is LayerOrigin PureHMO — and Why Does It Matter?
LayerOrigin PureHMO is built around a single HMO: 2'-fucosyllactose (2'-FL). 2'-FL is the most abundant HMO in human milk and has a well-established research profile — including clinical evidence that it supports gut microbiota diversity and is well tolerated in adults (PMID 27719686). This is a real supplement with real science behind it.
The question isn't whether 2'-FL is effective. It is. The question is: does a single HMO deliver what the full spectrum of breast milk HMOs delivers? And here the science is clear.
Why HMO Diversity Is the Whole Point
Breast milk contains more than 150 distinct HMO structures. That's not an accident of biology — it's a feature. Different HMO types serve different functions in the gut:
- Fucosylated HMOs (like 2'-FL) selectively feed Bifidobacterium and act as decoy receptors for fucose-binding pathogens
- Sialylated HMOs target a different set of pathogens and support neurological signaling and immune cell function
- Neutral (non-fucosylated, non-sialylated) HMOs provide additional prebiotic substrates that support microbial diversity more broadly
A 2025 review in Microorganisms confirmed that HMOs exert region-specific effects throughout the gastrointestinal tract — from inhibiting pathogen adhesion in the stomach to strengthening the gut barrier and enhancing SCFA production in the colon (PMID 41597549). These effects depend on the structural diversity of the HMOs present. No single HMO type captures all of them.
When researchers tested two HMO types together (2'-FL and lacto-N-neotetraose) in a 100-person RCT of healthy adults, they found the combination was well tolerated and produced meaningful shifts in intestinal microbiota composition (PMID 27719686). This is exactly the logic behind multi-HMO supplementation: more structural types, broader coverage, more complete gut response.
A 2025 Stanford RCT published in Cell Reports Medicine showed that even a single HMO can meaningfully alter the gut microbiome, circulating hormones, and metabolites in older adults (PMID 40738103). If one HMO can shift this much, consider what a full-spectrum HMO ingredient engineered to mirror breast milk composition might do.
What Makes kpHMO™ Different?
kēpos features kpHMO™, a proprietary human milk bioactive ingredient designed and owned exclusively by kēpos, formulated to best match the oligosaccharide composition found in real breast milk. Unlike single-strain HMO products, kpHMO™ covers all neutral, fucosylated, and sialylated HMO bases — delivering the full functional spectrum rather than a single isolated compound.
This matters for real-world gut health. A clinical trial examining HMO supplementation (2'-FL plus LNT) in adults with IBS documented significant modulation of fecal bifidobacteria abundance, microbiota composition shifts, and changes in gut metabolite profiles — evidence that multiple HMO types together produce a multi-pronged prebiotic effect (PMID 34836092).
A 2022 review further confirmed that HMOs may support symptom management in IBS through their combined prebiotic selectivity, anti-inflammatory properties, and gut barrier effects — effects that are driven by the structural diversity of HMOs, not by any single molecule in isolation (PMID 36557589).
Learn more about what HMOs are and how they work or explore the broader evidence for HMO benefits in adults.
The Lactoferrin Factor: Where the Comparison Ends Entirely
LayerOrigin PureHMO doesn't contain lactoferrin. kēpos does — and this is perhaps the single biggest differentiating factor in terms of what the science supports.
effera™ is a recombinant human lactoferrin produced via precision fermentation to be structurally identical to the lactoferrin found in breast milk. This matters because not all lactoferrin is equivalent. Bovine lactoferrin — the form used in most other supplements — differs from human lactoferrin in its amino acid sequence, glycosylation pattern, and receptor binding specificity.
These structural differences have measurable effects. A 2026 randomized, double-blind, parallel-arm trial published in the Journal of Dietary Supplements compared high-dose effera® (human LF, 3.4 g/day), low-dose effera® (0.34 g/day), and bovine lactoferrin (3.4 g/day) in 66 healthy adults over 28 days. The trial found that effera® (human lactoferrin) and bovine lactoferrin produced distinct effects on the adult gut microbiome. Notably, bovine lactoferrin was associated with significant unintended compositional shifts in gut bacteria over time, while effera® demonstrated a more stable, physiologically aligned microbiome response (PMID 42178844). This is direct head-to-head evidence that the source of lactoferrin matters.
Beyond gut microbiome effects, clinical data published in 2026 in Cureus documented that recombinant human lactoferrin supplementation may support healthy iron status without supplemental iron — a meaningful finding for anyone managing energy, fatigue, or immune function (PMID 42022247).
Side-by-Side: What the Evidence Actually Supports
When you compare the two approaches through the lens of the current science:
- HMO coverage: Single-HMO (2'-FL only) vs. full-spectrum multi-HMO (kpHMO™ — neutral, fucosylated, and sialylated types). Research shows the full spectrum is functionally richer.
- Lactoferrin: None vs. effera™ recombinant human lactoferrin. A 2026 RCT demonstrates human LF produces distinct and more physiologically aligned gut microbiome effects than bovine alternatives.
- Iron + gut health synergy: Not addressed vs. clinically documented through human lactoferrin supplementation.
- Synergistic design: kēpos was formulated to pair HMOs with lactoferrin — mirroring breast milk's dual-bioactive protective strategy in a single supplement.
This isn't about dismissing the value of 2'-FL. It's about recognizing that a full-spectrum HMO ingredient combined with recombinant human lactoferrin is simply a more complete science-aligned solution — and the data increasingly supports that conclusion.
The Bottom Line
If you're evaluating HMO supplements, the core question is: how closely does this product mirror the bioactive composition of breast milk, and does the research back it up?
The answer points toward multi-HMO coverage over single-HMO isolation, and toward recombinant human lactoferrin over no lactoferrin — or bovine alternatives. kēpos was designed from the ground up to deliver exactly that combination: kpHMO™ (designed and owned exclusively by kēpos) paired with effera™ recombinant human lactoferrin, together forming the most complete HMO-based gut health supplement available.
Ready to experience the full-spectrum approach? Explore kēpos and see what the science-backed combination of kpHMO™ and effera™ can do for your gut.
Frequently Asked Questions
Is 2'-FL the best HMO for gut health?
2'-FL is the most studied HMO and has strong clinical evidence for gut microbiota support. However, it is just one of over 150 distinct HMO structures found in breast milk. Research suggests that a broader spectrum of HMO types delivers more comprehensive prebiotic effects, covering different functional roles including pathogen blocking, barrier support, and selective microbiota feeding that individual HMOs cannot fully replicate alone.
What is effera™ and how is it different from bovine lactoferrin?
effera™ is a recombinant human lactoferrin produced through precision fermentation — structurally identical to the lactoferrin found in human breast milk. Bovine lactoferrin, found in most other supplements, differs in amino acid sequence, glycosylation pattern, and receptor specificity. A 2026 RCT found these differences translate to measurable differences in adult gut microbiome response, with human lactoferrin producing a more physiologically stable profile (PMID 42178844).
Why does kpHMO™ cover multiple HMO types instead of one?
kpHMO™ is a proprietary ingredient designed and owned exclusively by kēpos, formulated to mirror the full oligosaccharide spectrum of breast milk. Different HMO structural types serve different biological functions — fucosylated HMOs target certain pathogens, sialylated HMOs serve immune and neurological roles, and neutral HMOs offer additional prebiotic substrate diversity. No single HMO type provides all of these effects.
Do HMO supplements actually work in adults?
Yes — growing clinical evidence supports HMO efficacy in adults. A 2025 Stanford RCT showed a single HMO altered gut microbiome composition, circulating hormones, and metabolites in older adults. Multiple clinical trials in IBS patients and healthy adults have documented microbiota shifts, metabolite changes, and gut symptom improvements. A 2025 review confirmed HMOs reach the colon structurally intact in adults, where they exert functional effects (PMID 41597549).
Can kēpos support iron levels as well as gut health?
effera™ recombinant human lactoferrin in kēpos may support healthy iron status. A 2026 clinical report in Cureus documented that recombinant human lactoferrin supplementation may improve iron status without supplemental iron — relevant for adults managing energy levels, immune function, or iron absorption challenges (PMID 42022247).
